Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Leslie Magtanong Clear advanced filters

  • Magtanong et al. describe the first study to systematically analyze dosage suppression, a type of genetic interaction in which increased dosage of one gene compensates for mutation in another. The authors also develop reagents for future large-scale studies of dosage suppression.

    • Leslie Magtanong
    • Cheuk Hei Ho
    • Charles Boone
    Research
    Nature Biotechnology
    Volume: 29, P: 505-511

  • In chemical-genetic and lipidomics analyses, the clinical candidate oncology drug tegavivint induced an unconventional form of nonapoptotic cell death that required the lipid metabolic enzyme trans-2,3-enoyl-CoA reductase.

    • Logan Leak
    • Ziwei Wang
    • Scott J. Dixon
    Research
    Nature Chemical Biology
    P: 1-12

  • Kinetic modulatory profiling identifies regulators of ferroptosis, including the FDA-approved drug bazedoxifene, which acts in an off-target manner as a radical trapping antioxidant while mTOR inhibitors increased resistance to ferroptosis.

    • Megan Conlon
    • Carson D. Poltorack
    • Scott J. Dixon
    Research
    Nature Chemical Biology
    Volume: 17, P: 665-674

  • A synthetic lethal CRISPR–Cas9 screen identifies ferroptosis suppressor protein 1 as a key ferroptosis-resistance factor, the expression of which correlates with ferroptosis resistance in hundreds of cancer cell lines.

    • Kirill Bersuker
    • Joseph M. Hendricks
    • James A. Olzmann
    Research
    Nature
    Volume: 575, P: 688-692